Clinical trials: Bladder Tumors
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the…
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms
- Trial name
- EV-103 (NCT03288545)
- Testing
- enfortumab vedotin (EV), pembrolizumab, cisplatin
- Where
- 106 sites in United States, Canada and 4 more
- Volunteers
- 348 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate or Bladder Cancer
Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.
Pelvic lymph node dissection (PLND) is the most accurate staging tool to determine lymph node involvement in prostate and bladder cancer.
- Trial name
- NCT02001857
- Testing
- 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- University Hospital, Ghent
Bladder Cancer, Non-muscle Invasive Bladder Cancer
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
Blue light cystoscopy (BLC) is a diagnostic procedure in bladder cancer where the inside of the bladder is observed with a camera to detect bladder lesions.
- Trial name
- ENAiBLE (NCT07144319)
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 500 people
- Sponsor
- Photocure
Non-Muscle Invasive Bladder Carcinoma
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
This phase IV trial studies whether there is a relationship between how a patient is positioned while receiving bacillus Calmette Guerin (BCG) within the bladder (intravesical) and how long BCG stays in the bladder (dwell time)…
- Trial name
- NCT07474519
- Testing
- Accelerometry, BCG Solution, Electronic Health Record Review
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Bladder Cancer
Determinants of Bladder Cancer Recurrence Study (The DETER Study)
The purpose of this study is to learn how different lifestyle factors, such as cigarette smoking and body weight, change after a diagnosis of bladder cancer, and how they influence who gets a bladder cancer recurrence and who…
- Trial name
- NCT02400944
- Testing
- questionnaires, Saliva and/or urine sample
- Where
- 4 sites in United States
- Volunteers
- 600 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Bladder Cancer
Screening for Bladder Cancer
In the study proposed, up to 1,500 men age 60 and over with strong smoking histories will test their urine for the presence of blood daily for two 10-day testing periods with the Ames Hemastix.
- Trial name
- NCT00848627
- Testing
- Specimen and questionnaires only
- Where
- 3 sites in United States, Canada
- Volunteers
- 197 people
- Sponsor
- Baylor College of Medicine
Bladder Cancer
Urinary Microbiome Differences in Bladder Cancer, Benign Urinary Diseases and Healthy Counterparts in Adult Male Population
The study aims to investigate alterations in the bladder microbiome in adult men with bladder cancer, healthy men, and men with benign urinary disease
- Trial name
- NCT06992986
- Testing
- Investigating differences in the bladder microbiome
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Regina Elena Cancer Institute
Bladder Cancer
Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC
A randomized controlled trial aiming to investigate neoadjuvant, short-term intensive chemoresection with Mitomycin C compared to standard treatment with TURB and adjuvant intravesical instillation therapy in patients with…
- Trial name
- NICSA (NCT03348969)
- Testing
- Mitomycin c
- Where
- Denmark
- Volunteers
- 120 people
- Sponsor
- Jørgen Bjerggaard Jensen
Bladder Cancer
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Background: Bladder cancer is the sixth most common cancer in the United States. The way that doctors remove tumors in bladder surgeries may leave some cancer .
- Trial name
- NCT04235764
- Testing
- modified resectoscope, TURBT
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Neoplasm of Bladder, Muscle Invasive Bladder Carcinoma
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
The goal of this clinical trial is to determine if a partial cystectomy with extended pelvic lymph node removal will be effective at treating Muscle-Invasive Bladder Cancer instead of a complete cystectomy with extended pelvic…
- Trial name
- NCT06290687
- Testing
- Neoadjuvant Chemotherapy, Partial cystectomy with Extended pelvic lymph node dissection, Adjuvant systemic therapy
- Sponsor
- Case Comprehensive Cancer Center
Bladder Cancer, Disease Progression
In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?
Investigators aimed to evaluate the performance of The European Organization for Research and Treatment of Cancer(EORTC) and the Spanish Urology Association for Oncological Treatment(CUETO) risk tables on all non-muscle invasive…
- Conditions
- Bladder Cancer, Disease Progression, Recurrent Bladder Cancer
- Trial name
- NCT03174912
- Testing
- Intravesical BCG instillation
- Volunteers
- 400 people
- Sponsor
- Ankara Training and Research Hospital
Bladder Cancer
EpiCheck and Short-term Intensive Chemoresection in NMIBC
The aim of this explorative study is to evaluate whether EpiCheck can be used as a predictor of tumour response to short-term, intensive chemoresection with Mitomycin.
- Trial name
- NCT04162704
- Testing
- EpiCheck
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- Aarhus University Hospital
Non-muscle Invasive Bladder Cancer
Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients
To evaluate the clinical efficacy (median event-free survival) of APL-1202 in combination with Epirubicin hydrochloride versus Epirubicin hydrochloride alone in intermediate and high-risk chemo-refractory non-muscle invasive…
- Trial name
- ACCRUE (NCT04490993)
- Testing
- APL-1202 in combination with Epirubicin
- Where
- China
- Volunteers
- 359 people
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
Bladder Cancer
Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy such as fluorouracil and mitomycin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00024349
- Testing
- fluorouracil, mitomycin C, radiation therapy
- Where
- 27 sites in United Kingdom
- Volunteers
- 350 people
- Sponsor
- University Hospital Birmingham
Muscle-invasive Bladder Cancer
Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy
In this study, the relevant biomarkers for predicting the efficacy of neoadjuvant therapy in patients with MIBC were further explored.
- Trial name
- NCT07440901
- Testing
- Immunotherapy plus chemotherapy
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Muscle-Invasive Bladder Cancer (MIBC)
Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer
This study aims to evaluate the efficacy and safety of neoadjuvant trastuzumab rezetecan combined with adebrelimab for the treatment of HER2-positive muscle-invasive bladder cancer.
- Trial name
- NCT07624201
- Testing
- Trastuzumab Rezetecan Combined with Adebelizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Harbin Medical University
Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship
This phase I trial investigates how well a healthy eating program works in improving outcomes in patients with bladder cancer. The behavioral dietary program consists of educational materials, live phone calls, and interactive…
- Conditions
- Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Trial name
- NCT04548193
- Testing
- Behavioral Dietary Intervention, Educational Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Bladder Cancer
Study of Outcomes After Surgery/Treatment to Treat Bladder Cancer
The purpose of this study is to create a registry of older patients undergoing surgical and/or medical treatment for bladder cancer.
- Trial name
- PORCH (NCT01776138)
- Testing
- Collect Blood and Survey Instruments
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Bladder Cancer
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual…
- Trial name
- NCT06525571
- Testing
- Cysview, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University